Introduction: As recommended by WHO, regular calcium supplementation reduces the risk of preeclampsia. Limited food intake communities at high risk of preeclampsia also benefit from calcium supplementation. Preeclampsia and hypertension diseases are a leading cause of maternal mortality. Calcium supplementation is a low-risk, affordable measure to improve maternal and newborn health. Preeclampsia has complex causes and can only be treated by delivering the placenta. Calcium supplementation prevents nearly 50% of preeclampsia cases. Preeclampsia affects 2% of pregnancies and contributes to perinatal and maternal fatalities, mostly in low- and middle-income nations. Aims and Objective: To analyze the efficiency of calcium supplements in early pregnancy in preventing preeclampsia. Method: This study involved 90 participants in a randomized, double-blind, placebo-controlled design to evaluate a new obstetric care intervention’s efficacy and safety. Participants were assigned to either the Calcium group, receiving 1.5 g of Calcium daily after 20 weeks’ gestation, or the Placebo group. Primary and secondary outcomes were assessed after a 12-week period, and compliance was measured through surveys and follow-up. Inclusion criteria included women with a history of preeclampsia or eclampsia and an interest in future pregnancies. Exclusion criteria encompassed factors such as age, existing pregnancy, use of calcium supplements, certain medical conditions, and personal choices regarding contraception and consent. Results: The study found that the Placebo group had a higher rate of complications before allocation. Compliance rates were similar between the groups, indicating comparable adherence to the intervention. Pregnancy outcomes, including pregnancy loss rates and the frequencies of live births and pregnancies progressing to 20 weeks of gestation, did not significantly differ between the Calcium and Placebo groups. Preeclampsia occurrence showed no statistically significant difference between the groups. Other outcomes did not show significant changes, including gestational blood pressure, proteinuria, pregnancy loss, preeclampsia severity, preeclampsia onset, and maternal problems. However, more individuals in the Calcium group required postpartum hospitalization of 7 days or longer compared to the Placebo group. The study found no statistically significant differences between the two groups in most outcomes assessed. Conclusion: The study has concluded that Calcium can significantly prevent preeclampsia in early pregnancy.

Introduction: As recommended by WHO, regular calcium supplementation reduces the risk of preeclampsia. Limited food intake communities at high risk of preeclampsia also benefit from calcium supplementation. Preeclampsia and hypertension diseases are a leading cause of maternal mortality. Calcium supplementation is a low-risk, affordable measure to improve maternal and newborn health. Preeclampsia has complex causes and can only be treated by delivering the placenta. Calcium supplementation prevents nearly 50% of preeclampsia cases. Preeclampsia affects 2% of pregnancies and contributes to perinatal and maternal fatalities, mostly in low- and middle-income nations. Aims and Objective: To analyze the efficiency of calcium supplements in early pregnancy in preventing preeclampsia. Method: This study involved 90 participants in a randomized, double-blind, placebo-controlled design to evaluate a new obstetric care intervention’s efficacy and safety. Participants were assigned to either the Calcium group, receiving 1.5 g of Calcium daily after 20 weeks’ gestation, or the Placebo group. Primary and secondary outcomes were assessed after a 12-week period, and compliance was measured through surveys and follow-up. Inclusion criteria included women with a history of preeclampsia or eclampsia and an interest in future pregnancies. Exclusion criteria encompassed factors such as age, existing pregnancy, use of calcium supplements, certain medical conditions, and personal choices regarding contraception and consent. Results: The study found that the Placebo group had a higher rate of complications before allocation. Compliance rates were similar between the groups, indicating comparable adherence to the intervention. Pregnancy outcomes, including pregnancy loss rates and the frequencies of live births and pregnancies progressing to 20 weeks of gestation, did not significantly differ between the Calcium and Placebo groups. Preeclampsia occurrence showed no statistically significant difference between the groups. Other outcomes did not show significant changes, including gestational blood pressure, proteinuria, pregnancy loss, preeclampsia severity, preeclampsia onset, and maternal problems. However, more individuals in the Calcium group required postpartum hospitalization of 7 days or longer compared to the Placebo group. The study found no statistically significant differences between the two groups in most outcomes assessed. Conclusion: The study has concluded that Calcium can significantly prevent preeclampsia in early pregnancy.